Irinotecan

KRAS Gene Mutation

Cardiff OncologySmall moleculePhase 1/2Dormant

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 95/ 100

Competitive context

13 Active assets in the KRAS Gene Mutation cohort.

Asset / Sponsor	Phase	Rating
gsk1120212 Memorial Sloan Kettering Cancer Center	Phase 2	BB
METHOTREXATE Stanford University	Phase 2	B
5-azacytidine Stanford University	Phase 2	B
Palbociclib Calithera Biosciences, Inc	Phase 1/2	B
Regorafenib Stanford University	Phase 2	B

View all 30 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant

BBB

Indicative ·

78 / 100

exocrine pancreatic carcinomaDormant

BBB

Indicative ·

78 / 100

Peritoneal NeoplasmsDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.